High Cost of New Drugs Weighs on Medicaid

A U.S. District Court case highlights brewing concerns over the high costs of specialty drugs such as Kalydeco, which was approved by the U.S. Food & Drug Administration in 2012 and treats some cystic fibrosis patients at an approximate annual cost of $300,000.
Source: Arkansas Business - Health Care - Category: American Health Source Type: news